Vertex Pharmaceuticals Incorporated (VRTX)
| Market Cap | 136.87B +27.1% |
| Revenue (ttm) | 12.59B +10.2% |
| Net Income | 4.41B +21.1% |
| EPS | 17.18 +22.1% |
| Shares Out | 253.46M |
| PE Ratio | 31.43 |
| Forward PE | 28.08 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,542,075 |
| Open | 536.46 |
| Previous Close | 529.69 |
| Day's Range | 534.01 - 546.61 |
| 52-Week Range | 403.16 - 560.25 |
| Beta | 0.28 |
| Analysts | Buy |
| Price Target | 571.46 (+5.83%) |
| Earnings Date | Nov 2, 2026 |
About VRTX
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMK... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 32 analysts, the average rating for VRTX stock is "Buy." The 12-month stock price target is $571.46, which is an increase of 5.83% from the latest price.
News
Vertex Pharmaceuticals Transcript: American Society of Nephrology (ASN) Kidney Week 2026
AMPLITUDE is fully enrolled, with interim results expected early next year and FDA discussions anchored to one-year eGFR. Povetacicept showed a 52% week-36 proteinuria reduction in IgAN; coverage announcements are expected in H1 2027.
Vertex Pharmaceuticals Slides: FY 2026
Vertex Pharmaceuticals has posted slides in relation to its FY 2026 quarterly earnings report, which was published on October 23, 2026.
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), p...
Vertex Appoints Daniel Brennan to its Board of Directors
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Daniel Brennan has been appointed to its Board of Directors as an independent director. Mr. Brennan has...
Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism
Biotechnology stocks are showing signs of a renewed recovery, supported by a pickup in pharmaceutical mergers and acquisitions and investor interest in drug development pipelines. Key Takeaways: Big p...
Vertex Pharmaceuticals price target lowered to $667 from $672 at BofA
BofA lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $667 from $672 and keeps a Buy rating on the shares after updating estimates ahead of the company’s Q3…
Vertex Pharmaceuticals to present data on Alyftrek at NACFC
Vertex Pharmaceuticals (VRTX) announced new interim data from the ALYFTREK 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that a...
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label exten...
Vertex Pharmaceuticals price target raised to $576 from $570 at RBC Capital
RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $576 from $570 and keeps an Outperform rating on the shares as part of a broader research note…
Vertex to Announce Third Quarter 2026 Financial Results November 2nd
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2026 financial results on Monday, November 2, 2026, after the financial markets close. The com...
Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins 'Closing Bell Overtime' to talk biotech innovations in China.
The Top HealthTech Questions Landing on Our Desks
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled th...
Vertex Pharmaceuticals price target raised to $615 from $585 at UBS
UBS raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $615 from $585 and keeps a Buy rating on the shares. Vertex’s key near-term catalyst is the early-2027 Phase…
Vertex Pharmaceuticals price target raised to $615 from $585 at UBS
UBS raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $615 from $585 and keeps a Buy rating on the shares. Vertex’s key near-term catalyst is an early-2027 interim…
Vertex's Kidney Drug Success Sparks a 22% Surge for This Rival Biotech
Maze Therapeutics stock jumped after Vertex Pharmaceuticals reported positive results for inaxaplin, boosting confidence in a rival treatment from Maze.
Truist sees ‘significant positive readthrough’ for Maze from Vertex data
Truist analyst Danielle Brill views Vertex’s (VRTX) positive Phase 2 topline data as a meaningful validation of APOL1 inhibition in classic APOL1-mediated kidney disease and estimates the data support...
Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study
The company states: “Vertex Pharmaceuticals (VRTX) announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease – AMKD – and modest proteinuri...
Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease...
Vertex Pharmaceuticals partners with Lindsey Vonn for JOURNAVX awareness
Vertex Pharmaceuticals (VRTX) has partnered with world champion skier Lindsey Vonn to raise awareness of JOURNAVX, a prescription non-opioid medicine for the treatment of moderate-to-severe acute pain...
Vertex Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The company is advancing a diversified pipeline with global launches in cystic fibrosis, expansion in renal and rare endocrine diseases, and promising assets in acute pain, diabetes, and genetic kidney disorders. Key near-term milestones include pivotal readouts for pove and inaxaplin, and continued rollout of ALYFTREK.
Strong Core Business, Raised Guidance Push Vertex Pharmaceuticals Higher
Since 2008, Vertex Pharmaceuticals, Inc. (VRTX) shares have received 42 outlier institutional inflow signals and gained over 1,682%.
Vertex Pharmaceuticals reinstated with an Overweight at JPMorgan
JPMorgan reinstated coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating and price target of $560, up from $515, following a period of restriction. Vertex continues to expand with the…
Vertex Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The conference highlighted a diversified portfolio strategy, with recent acquisitions accelerating expansion into rare endocrine and renal diseases. Key near-term catalysts include regulatory milestones for povetacicept and inaxaplin, while commercial infrastructure has matured to support complex launches. PALSONIFY and atumelnant are positioned as major growth drivers.
Vertex Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference
Multiple near-term catalysts are expected, including pivotal renal data, a major IgAN launch, and key readouts in pain and rare diseases. Commercial strategies focus on clinical differentiation, patient access, and global expansion, with a vision for diversified revenue across five therapeutic pillars by 2027.